Caraco v. Novo Nordisk — Generic Drugmakers May Challenge Overbroad Orange Book Use Codes

Background

Novo Nordisk held patents on repaglinide, a diabetes drug it sold under the brand name Prandin. The drug was approved by the FDA for treating type 2 diabetes. Novo listed two patents in the FDA’s Orange Book — the official database of approved drugs and their associated patents that generic manufacturers must navigate before seeking FDA approval.

Caraco Pharmaceutical wanted to sell a generic version of repaglinide for uses not covered by Novo’s patents. Under the Hatch-Waxman Act, generic manufacturers can file a “Paragraph IV” certification challenging a listed patent, which triggers a 30-month stay on FDA approval but also starts litigation. Novo submitted an overly broad “use code” to the FDA that described the patented method as covering all approved uses of the drug — not just the specific method protected by the patent. This effectively blocked Caraco from obtaining FDA approval even for the non-patented uses.

The Court’s Holding

Justice Kagan, writing unanimously for the Court, held that the Hatch-Waxman Act permits a generic manufacturer to bring a counterclaim seeking to “correct” an overbroad use code in the Orange Book. The statute expressly allows generic companies to challenge use codes that inaccurately describe the scope of a listed patent, and courts have authority to order the brand-name company to amend its submission.

The Court read the counterclaim provision broadly, focusing on the word “correct” — which encompasses correcting false or misleading information in the Orange Book, not just deleting a patent from the listing entirely. Novo’s argument that the counterclaim applied only to the presence of a patent in the listing (not to the accuracy of use codes) was rejected as inconsistent with the statute’s text and purpose.

Key Takeaways

• Generic drug makers can bring counterclaims under the Hatch-Waxman Act to correct overbroad Orange Book use codes that improperly block FDA approval of non-patented uses.
• Brand-name companies cannot use inflated use codes as a strategic weapon to delay generic competition beyond the scope of their actual patent protection.
• The ruling reinforces the balance Congress struck in Hatch-Waxman between incentivizing pharmaceutical innovation and ensuring timely generic market entry.
• Accurate Orange Book submissions are legally required, and overstating patent coverage in use codes carries litigation risk.

Why It Matters

Orange Book use codes sit at the crossroads of patent law and FDA regulatory strategy. Brand-name pharmaceutical companies sometimes file use codes that describe their patented method more broadly than the patent actually covers, effectively converting a limited patent into a blockade against all generic competition for an approved drug. Caraco closed this loophole by confirming that generic manufacturers have a statutory remedy to challenge such tactics.

The decision matters for anyone involved in pharmaceutical patent disputes, drug pricing policy, or healthcare access. It ensures that the Hatch-Waxman framework — designed to create a pathway for generic drugs to reach patients faster — cannot be easily circumvented through Orange Book manipulation. Generic manufacturers, insurers, and patients all benefit when patent protections are accurately scoped and enforced.